Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC41H42FN7O10 |
InChIKeyKZECCLCVBAHYOC-UHFFFAOYSA-N |
CAS Registry- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 28 Oct 2019 |





